http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1249870399170/prdetail.htm
Melbourne, Australia — 11/09/2009
CSL Limited, Australia’s leading biopharmaceutical company, announced today that preliminary data from the first study of its candidate pandemic H1N1 vaccine demonstrated a robust immune response in healthy adults after a single unadjuvanted15mcg dose.
The preliminary data, published today as an original article in the New England Journal of Medicine, showed that over 95% of participants receiving the single 15mcg dose of the vaccine achieved antibody levels that correlate with the prevention of influenza infection.1
The study also shows that the vaccine has a tolerability profile consistent with seasonal influenza vaccines.
http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1249870399170...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.58 |
Change
-1.210(0.40%) |
Mkt cap ! $145.5B | |||
| Open | High | Low | Value | Volume |
| $300.74 | $300.99 | $298.81 | $240.1M | 820.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $300.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.59 | 836 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |